AMSTERDAM, Oct 15 (Reuters) - A shareholder in Dutch biotech Crucell (CRCL.AS), subject to an agreed offer by U.S.-based Johnson & Johnson (JNJ.N), has sold all its shares in the firm, underlining market doubts a higher offer will emerge.
AMSTERDAM, Oct 15 (Reuters) - A shareholder in Dutch biotech Crucell (CRCL.AS), subject to an agreed offer by U.S.-based Johnson & Johnson (JNJ.N), has sold all its shares in the firm, underlining market doubts a higher offer will emerge.
